D9169BZ
Brachytherapy Salivary Glands to None with Palladium 103 (Pd-103), High Dose Rate (HDR) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | 9 Ear, Nose, Mouth and Throat |
| Operation | 1 Brachytherapy |
| Body Part | 6 Salivary Glands |
| Approach | 9 High Dose Rate (HDR) |
| Device | B Palladium 103 (Pd-103) |
| Qualifier | Z None |
Procedure Overview
Brachytherapy for ear, nose, mouth, and throat conditions involves placing a radioactive source directly into or next to a tumor, commonly in the oral cavity, tongue base, or nasopharynx. Because the source sits so close to the target tissue, it delivers a concentrated dose to the tumor while limiting exposure to surrounding healthy structures, which is valuable in a region crowded with nerves and tissue responsible for speech and swallowing.
The radioactive material may be temporary, removed after a set period, or permanently implanted depending on the isotope and clinical goal. This approach is often used alongside external beam radiation or surgery, particularly when a tumor recurs or when sparing normal tissue is a priority.
Anatomy & Axis Detail
Salivary Glands
The salivary glands, most often the parotid or submandibular glands when brachytherapy is used, may receive implanted radioactive sources when a tumor is localized enough to allow interstitial placement, typically as a boost following resection or external radiation. Because glandular tissue is arranged around branching ducts and is closely associated with the facial nerve in the parotid, source placement demands attention to these structures to avoid unnecessary injury during catheter insertion. This approach allows a concentrated dose to residual or high-risk tissue while limiting radiation exposure to the surrounding gland and adjacent skin compared to broader external fields. Given that saliva production depends on preserving as much healthy glandular tissue as possible, brachytherapy's localized nature is often chosen specifically to protect function in the uninvolved portions of the gland.
Modality Qualifier: High Dose Rate (HDR)
High Dose Rate (HDR) identifies brachytherapy delivered with a radioactive source of high activity, allowing treatment to be completed in minutes per fraction, often on an outpatient basis with afterloading applicators. It contrasts with Low Dose Rate (LDR), which uses a weaker source left in place for hours to days, trading a longer treatment time for a different radiobiological effect and staffing exposure profile.
Isotope: Palladium 103 (Pd-103)
Palladium-103 is another low-dose-rate isotope used in permanent interstitial seed implants, chiefly for prostate brachytherapy, but its shorter half-life (about 17 days) delivers its therapeutic dose faster than I-125. Clinicians may favor it for higher-grade or faster-growing tumors where a more concentrated early dose is desired, while I-125 remains preferred for lower-risk, slower disease.
Coding & Documentation
Coders need documentation identifying the specific isotope or source used and confirming that the radioactive material was placed within or immediately adjacent to the target structure, not delivered from an external machine. The procedure note should specify whether the source is temporary or permanent, since this affects the qualifier assigned.